stockrowSarepta Therapeutics, Inc.
SRPT Healthcare Biotechnology
Sarepta Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 15.6% from fiscal 2024.
- Revenue
- −4.51%
- EPS
- +46.0%
- Free cash flow
- +231.8%
- Total debt
- −17.2%
Quarter to September 2026, against a year earlier
Follow SRPT
Alert me
Sarepta Therapeutics, Inc. (SRPT) P/B ratio
As of 6 November 2026, Sarepta Therapeutics, Inc. (SRPT) trades at a P/B ratio of 1.2×. Over the past ten years it has ranged from 0.9× (July 2025) to 35.5× (March 2023); the current reading is higher than 2% of that period. That is below the Biotechnology industry median of 2.1× and below the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 1.9× | (75.04%) |
| FY2024 | 7.6× | (26.85%) |
| FY2023 | 10.3× | (63.57%) |
| FY2022 | 28.4× | 260.11% |
| FY2021 | 7.9× | (54.81%) |
| FY2020 | 17.4× | 50.28% |
| FY2019 | 11.6× | 65.77% |
| FY2018 | 7.0× | 61.33% |
| FY2017 | 4.3× | 7.50% |
| FY2016 | 4.0× | (52.89%) |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 1.3× | 1.80% |
| Jun 2026 | 1.2× | (18.30%) |
| Mar 2026 | 1.5× | (19.65%) |
| Dec 2025 | 1.9× | 29.10% |
| 35 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| SRPT Sarepta Therapeutics, Inc. | 1.2× |
| HRMY Harmony Biosciences Holdings, Inc. compare | 1.8× |
| MESO Mesoblast Limited compare | 1.9× |
| VIR Vir Biotechnology, Inc. compare | 2.3× |
| MRVI Maravai LifeSciences Holdings, Inc. compare | 3.3× |
| MAZE Maze Therapeutics, Inc. compare | 4.5× |
| TRVI Trevi Therapeutics, Inc. compare | 6.9× |
| REPL Replimune Group, Inc. compare | 11.2× |
| TRAX First Tracks Biotherapeutics, Inc. compare | 11.3× |
| Biotechnology industry median | 2.1× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))